| abstract |
Aglycodendrimer comprising: a) a non-toxic dendrimer polypropyletherimine core supporting 16 terminal carboxylic acid groups, and b) conjungated to said core 2, 3, 4 or 5 glucosaminemolecules, wherein each glucosamineis linked directly through a zero length amide bond with a residue of a terminal carboxylic acid group. The invention also extends to defined populations comprising said glycodendrimer molecules, pharmaceutical compositions comprising said molecules or populations, process for preparing the molecules and formulations, and therapeutic used of the molecules, populations and compositions. |